HUB Organoids for drug screening

About HUB Organoids for drug screening

HUB Organoids™ are one-of-a-kind models that can be developed from any epithelial disease and any patient, thus bridging the gap between the lab and the clinic and effectively bringing “Patients inside the lab”. HUB Organoids accurately predict patient response, thus representing an ideal model to test drug efficacy and toxicity and stratify patient populations based on in vitro sensitivity data. Our Clinical Trials in a Dish (CTiD) platform can support your preclinical drug development by helping you select a candidate from your lead compound library. HUB Organoids can also support clinical trials in "co-clinical" applications whereby organoids are developed from patient biopsies while they are enrolled in a clinical trial (Phase I to III). In this settings HUB Organoids are treated similarly to patients in the clinic to prospectively identify responders and non-responders in subsequent trials or after market entry and investigate the mechanism of response or lack of response in patients

Keywords

• Biomarker Identification
• Companion Diagnostics
• Drug Development
• Drug Screeening
• Organoids
• Patient Stratification
• Personalized Medicine
• Precision Medicine

Address

• Headquarters

  Yalelaan 623584CM UtrechtUtrecht, Netherlands